Loading...
Loading...
  • Our Take On Spectrum Pharmaceuticals, Inc. (SPPI)’s Near Term Panel Review
    Insider Monkey7 days ago

    Our Take On Spectrum Pharmaceuticals, Inc. (SPPI)’s Near Term Panel Review

    Next month, an advisory panel will get together to discuss, and rule upon, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s lead bladder cancer development candidate, apaziquone. The agency accepted the company’s NDA back in February, and has set a PDUFA date of December 11, 2016. There’s a bit of distance between advisory review and PDUFA (often it is […]

  • Capital Cube15 days ago

    ETF’s with exposure to Spectrum Pharmaceuticals, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Spectrum Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to SPPI-US. Comparing the performance and risk of Spectrum Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube18 days ago

    Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Spectrum Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Spectrum Pharmaceuticals, Inc. – Teva Pharmaceutical Industries Limited Sponsored ADR, Celgene Corporation, Curis, Inc., Seattle Genetics, Inc., Sagent Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, ... Read more (Read more...)